Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Low-level radiation exposure poses less of a health risk than other modern lifestyle threats, such as smoking, obesity and air pollution, according to Oxford University research.

© Shutterstock

Image courtesy of Shutterstock

Human populations have always been exposed to ionizing radiation, and more so in modern life due to its use in medicine, industry and the armed forces. Whilst the risks to human health from medium and high-level radiation are relatively well-understood, the risks at lower levels are less clear. Mixed messages about the safety of low doses of radiation from different sources have created confusion for the public and for policy makers.  

In a new study published in the Proceedings of the Royal Society, a team of experts from the Oxford Martin School at the University of Oxford have compiled the evidence on health risks from low-level ionizing radiation, adding a new nuance to the debate. The restatement is intended to better inform policy decisions and show where crucial gaps in knowledge lie. It clarifies the scientific evidence available from a variety of sources, and ranks them as to how much they enjoy consensus support from the scientific community.  The paper concludes that the overall risk to human health from low-level radiation exposure is small, particularly when compared with general risks from modern society, such as obesity, smoking and air pollution.

Read more

Similar stories

Oxford vaccine creator Professor Sarah Gilbert awarded RSA Albert Medal

Awards and Appointments Coronavirus COVID-19 General Innovation Research

Professor Sarah Gilbert has been awarded the Royal Society for Arts, Manufactures and Commerce’ (RSA) Albert Medal for her work on the Oxford vaccine.

PRINCIPLE Covid-19 treatments trial widens to under 50s and adds colchicine

Clinical Trials Coronavirus COVID-19 General Research

From today, the UK’s national priority platform trial of Covid-19 treatments for recovery at home launches its investigation of the gout drug colchicine, and expands for the first time to include adults of any age.

Regular meat consumption linked with a wide range of common diseases

Research

Regular meat consumption is associated with a range of diseases that researchers had not previously considered, according to a large, population-level study conducted by a team at the University of Oxford.

New data show vaccines reduce severe COVID-19 in older adults

Coronavirus COVID-19 Research

New data show both Oxford / AstraZeneca vaccine and the Pfizer-BioNTech vaccines significantly reduce severe COVID-19 in older adults.

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.